BMRN logo

BioMarin Pharmaceutical Inc.

BMRN
Healthcare|Biotechnology|US
$56.03
-0.09 (-0.16%)
DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80

Financials

Financial Snapshot

Market Cap
$10.85B
Enterprise Value
$14.30B
Revenue (TTM)
$3.66B
Net Income (TTM)
-$19.1M
Cash & Investments
$736.0M
Net Cash
-$3.45B
Free Cash Flow (TTM)
$557.9M
Operating CF (TTM)
$676.6M
Debt/Equity
0.67

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$789.7M$1.40B$1.08B$753.8M$1.07B$1.01B$1.29B$1.07B$1.14B$1.56B$736.0M
Operating Cash Flow
-$227.8M-$8.8M$20.2M$48.3M$85.4M$304.5M$175.9M$159.3M$572.8M$828.0M$676.6M
Free Cash Flow
-$376.2M-$208.0M-$124.4M-$96.8M-$52.2M$185.3M$54.9M$51.6M$475.4M$725.0M$557.9M
Capital Expenditure
-$148.4M-$199.2M-$144.6M-$145.0M-$137.5M-$119.2M-$121.0M-$107.6M-$97.4M-$103.0M-$118.8M
Financing Cash Flow
$727.1M$507.1M-$388.0M-$74.7M$181.1M-$48.0K-$18.6M-$18.7M-$526.4M-$42.4M$3.54B

R&D Spending

R&D (TTM)
$758.7M
R&D Intensity
20.8%
R&D Growth vs Prior
-17.7%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$1.12B$1.31B$1.49B$1.70B$1.86B$1.85B$2.10B$2.42B$2.85B$3.22B$3.66B
R&D Expense
$661.9M$610.8M$696.3M$715.0M$628.1M$628.8M$649.6M$746.8M$747.2M$921.9M$758.7M
R&D % of Revenue
59.3%46.5%46.7%42.0%33.8%34.1%31.0%30.9%26.2%28.6%20.8%
SG&A
$476.6M$554.3M$604.4M$680.9M$737.7M$759.4M$823.2M$892.4M$1.01B$1.28B$1.79B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$1.12B$1.31B$1.49B$1.70B$1.86B$1.85B$2.10B$2.42B$2.85B$3.22B$3.66B
Cost of Revenue
$209.6M$241.8M$315.3M$359.5M$524.3M$470.5M$503.0M$532.1M$580.2M$736.8M$898.3M
Gross Profit
$907.2M$1.07B$1.18B$1.34B$1.34B$1.38B$1.59B$1.89B$2.27B$2.48B$2.76B
R&D
$661.9M$610.8M$696.3M$715.0M$628.1M$628.8M$649.6M$746.8M$747.2M$921.9M$758.7M
SG&A
$476.6M$554.3M$604.4M$680.9M$737.7M$759.4M$823.2M$892.4M$1.01B$1.28B$1.79B
Operating Income
-$803.4M-$14.7M-$123.5M-$100.5M-$43.4M-$82.3M$161.0M$185.8M$484.2M$533.5M$237.9M
Interest Expense
$39.5M$42.7M$43.7M$23.5M$29.3M$15.3M$16.0M$17.3M$12.7M$10.9M$136.7M
Pretax Income
-$831.0M-$35.9M-$142.7M-$94.8M-$49.0M-$75.3M$149.6M$188.6M$541.8M$482.5M$43.7M
Net Income
-$630.2M-$117.0M-$77.2M-$23.8M$854.0M-$64.1M$141.6M$167.6M$426.9M$348.9M-$19.1M
EPS (Diluted)
-3.79-0.67-0.44-0.134.53-0.350.750.882.211.80-0.08
EBITDA
-$698.0M$91.0M-$3.4M$31.9M$83.7M$47.4M$265.4M$306.8M$650.5M$572.9M$445.3M
Shares Out. (M)
166.22174.43177.27179.04191.68182.85188.96191.59196.71197.39193.59

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$408.3M$598.0M$494.0M$437.4M$649.2M$587.3M$724.5M$755.1M$942.8M$1.31B$736.0M
Short-Term Investments
$381.3M$797.9M$590.3M$316.4M$416.2M$426.6M$567.0M$318.7M$194.9M$248.9M$0.00
Total Current Assets
$1.42B$2.21B$2.06B$1.94B$2.34B$2.27B$2.75B$2.96B$3.23B$3.95B$3.92B
Total Assets
$4.02B$4.63B$4.43B$4.69B$5.85B$6.00B$6.38B$6.84B$6.99B$7.59B$11.57B
Total Current Liabilities
$439.3M$816.5M$523.2M$932.5M$492.5M$546.5M$588.9M$1.18B$607.0M$759.0M$1.60B
Long-Term Debt
$660.8M$813.5M$830.4M$486.2M$1.08B$1.08B$1.08B$593.1M$595.1M$597.2M$3.51B
Total Liabilities
$1.26B$1.82B$1.46B$1.57B$1.74B$1.74B$1.77B$1.89B$1.33B$1.51B$5.31B
Stockholders' Equity
$2.77B$2.81B$2.97B$3.12B$4.11B$4.27B$4.60B$4.95B$5.66B$6.09B$6.26B
Retained Earnings
-$1.52B-$1.64B-$1.69B-$1.72B-$861.6M-$930.8M-$789.2M-$621.6M-$194.7M$154.2M$181.7M

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
-$227.8M-$8.8M$20.2M$48.3M$85.4M$304.5M$175.9M$159.3M$572.8M$828.0M$676.6M
Capital Expenditure
-$148.4M-$199.2M-$144.6M-$145.0M-$137.5M-$119.2M-$121.0M-$107.6M-$97.4M-$103.0M-$118.8M
Free Cash Flow
-$376.2M-$208.0M-$124.4M-$96.8M-$52.2M$185.3M$54.9M$51.6M$475.4M$725.0M$557.9M
Investing Cash Flow
-$484.0M-$305.5M$264.4M-$31.0M-$53.6M-$366.3M-$20.0M-$111.2M$136.5M-$414.2M-$4.73B
Financing Cash Flow
$727.1M$507.1M-$388.0M-$74.7M$181.1M-$48.0K-$18.6M-$18.7M-$526.4M-$42.4M$3.54B
Issuance of Stock
$712.9M$60.9M$67.5M$31.6M$0.00$0.00$69.3M$69.4M$0.00$14.5M$14.4M
Repurchase of Stock
$0.00-$33.5M-$35.9M$0.00-$50.0M$0.00$0.00$0.00$0.00$0.00-$42.6M
Net Debt Issuance
$0.00$481.7M-$375.0M-$5.1M$203.8M-$3.0M-$2.6M-$2.3M-$495.0M$0.00$3.63B
Stock Based Comp.
$134.6M$140.3M$148.8M$159.9M$189.7M$197.3M$196.3M$207.1M$201.6M$181.4M$219.6M
Net Change in Cash
$11.3M$189.7M-$104.0M-$56.5M$211.7M-$61.9M$137.3M$30.6M$187.7M$368.8M-$514.1M

Dilution Tracker

Shares Outstanding
194M
5-Year Share Growth
+3.0%
Stock Issuance (TTM)
$14.4M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
166.22174.43177.27179.04191.68182.85188.96191.59196.71197.39193.59
Change vs Prior %
—4.9%1.6%1.0%7.1%-4.6%3.3%1.4%2.7%0.3%-1.9%
Stock Issuance
$712.9M$60.9M$67.5M$31.6M$0.00$0.00$69.3M$69.4M$0.00$14.5M$14.4M
Stock Repurchase
$0.00-$33.5M-$35.9M$0.00-$50.0M$0.00$0.00$0.00$0.00$0.00-$42.6M
Stock Based Comp.
$134.6M$140.3M$148.8M$159.9M$189.7M$197.3M$196.3M$207.1M$201.6M$181.4M$219.6M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
81.2%81.6%78.9%78.9%71.8%74.5%76.0%78.0%79.7%77.1%75.4%
Operating Margin %
-71.9%-1.1%-8.3%-5.9%-2.3%-4.5%7.7%7.7%17.0%16.6%6.5%
Net Margin %
-56.4%-8.9%-5.2%-1.4%45.9%-3.5%6.8%6.9%15.0%10.8%-0.5%
EBITDA Margin %
-62.5%6.9%-0.2%1.9%4.5%2.6%12.7%12.7%22.8%17.8%12.2%
FCF Margin %
-33.7%-15.8%-8.3%-5.7%-2.8%10.0%2.6%2.1%16.7%22.5%15.3%
ROE %
-22.8%-4.2%-2.6%-0.8%20.8%-1.5%3.1%3.4%7.5%5.7%-0.3%
ROA %
-15.7%-2.5%-1.7%-0.5%14.6%-1.1%2.2%2.5%6.1%4.6%-0.2%
ROIC %
-16.9%-0.4%-1.7%-0.6%14.1%-1.3%2.6%2.7%6.0%5.6%-1.0%
R&D / Revenue %
59.3%46.5%46.7%42.0%33.8%34.1%31.0%30.9%26.2%28.6%20.8%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
25.5%17.6%13.5%14.3%9.2%-0.8%13.5%15.4%18.0%12.9%
Gross Profit
23.0%18.1%9.7%14.3%-0.6%3.0%15.8%18.5%20.5%9.3%
Operating Income
-625.8%98.2%-740.3%18.7%56.8%-89.6%295.5%15.4%160.6%10.2%
Net Income
-266.8%81.4%34.0%69.1%3681.1%-107.5%320.9%18.4%154.6%-18.3%
EPS (Diluted)
-254.2%82.3%34.3%70.5%3584.6%-107.7%314.3%17.3%151.1%-18.6%
Operating Cash Flow
-2.8%96.2%330.8%138.8%76.9%256.7%-42.2%-9.5%259.7%44.5%
Free Cash Flow
16.3%44.7%40.2%22.2%46.1%455.3%-70.4%-6.0%820.5%52.5%
R&D Expense
4.3%-7.7%14.0%2.7%-12.2%0.1%3.3%15.0%0.1%23.4%
SG&A Expense
18.5%16.3%9.0%12.7%8.3%2.9%8.4%8.4%13.1%26.6%
Total Assets
7.9%15.1%-4.4%5.9%24.7%2.7%6.2%7.3%2.2%8.7%
Book Value / Share
11.1%-3.4%4.1%4.0%30.2%2.7%6.5%6.1%12.9%6.6%
Debt
3.2%71.9%-29.3%3.4%26.6%0.2%0.4%0.2%-40.7%-1.0%
Diluted Shares
3.9%4.9%1.6%1.0%7.1%-4.6%3.3%1.4%2.7%0.3%

Valuation

P/E (TTM)At Loss
10Y Low / Med / High18.46 / 32.65 / 136.17
P/S2.97
10Y Low / Med / High3.54 / 8.88 / 12.31
P/B1.73
10Y Low / Med / High1.87 / 4.17 / 5.54
EV/EBITDA32.12
10Y Low / Med / High18.73 / 177.32 / 487.47
EV/Revenue3.91
10Y Low / Med / High3.33 / 9.13 / 12.56
P/FCF19.44
10Y Low / Med / High15.72 / 87.18 / 350.66

Intrinsic Value Models (per share)

DCF Value
$7.43
Tangible Book / Share
$4.20
Cash / Share
$3.80
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
-21.80-133.09-193.52-650.3818.46-252.43136.17108.3429.2132.65-622.56
P/S Ratio
12.3111.8410.118.888.528.759.157.494.383.542.97
P/B Ratio
4.975.545.084.853.863.794.173.662.211.871.73
EV/EBITDA
-20.09177.32-4573.64487.47194.76351.1773.6460.1518.7518.7332.12
EV/Revenue
12.5612.2810.349.138.769.029.327.634.273.333.91

Analyst Estimates & Quality

Altman Z-Score
1.85
Grey Zone
Piotroski F-Score
2
Weak

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$3.87B$4.45B$4.83B
Net Income$589.7M$1.24B$1.52B
EPS$3.00$6.36$7.68
# Analysts (EPS)151512

Revenue Segments

By Product

Segment202020212022202320242025
Royalty And Other$54.6M$62.8M$54.0M$46.7M$44.5M$53.5M
Product—$1.78B$2.04B$2.37B$2.81B$3.17B
Enzyme Product———$1.72B——

By Geography

Segment201520162017201820192020
Europe$178.7M$252.6M$301.5M$436.4M$509.2M$518.5M
Latin America$142.3M$147.5M$182.4M$185.0M$218.8M$205.9M
Rest Of World$124.8M$209.2M$241.5M$172.9M$197.6M$223.8M
U S$444.1M—————
UNITED STATES—$507.5M$588.2M$696.8M$778.4M$912.4M